Corient Private Wealth LP Purchases New Position in West Pharmaceutical Services, Inc. $WST

Corient Private Wealth LP acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 65,759 shares of the medical instruments supplier’s stock, valued at approximately $23,607,000. Corient Private Wealth LP owned approximately 0.09% of West Pharmaceutical Services at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in WST. Bank of Nova Scotia boosted its position in West Pharmaceutical Services by 337.8% during the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock valued at $16,373,000 after acquiring an additional 50,402 shares during the last quarter. Hsbc Holdings PLC grew its holdings in West Pharmaceutical Services by 23.3% during the 4th quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock worth $40,425,000 after acquiring an additional 27,745 shares during the period. Renaissance Technologies LLC raised its position in shares of West Pharmaceutical Services by 100.2% in the 1st quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier’s stock worth $52,549,000 after acquiring an additional 104,924 shares in the last quarter. Conestoga Capital Advisors LLC lifted its stake in shares of West Pharmaceutical Services by 6.7% in the 1st quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock valued at $32,826,000 after purchasing an additional 8,179 shares during the period. Finally, Ilmarinen Mutual Pension Insurance Co acquired a new position in shares of West Pharmaceutical Services in the 4th quarter valued at about $3,027,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $338.21 on Friday. The business’s fifty day simple moving average is $350.55 and its 200 day simple moving average is $303.61. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12 month low of $223.83 and a 12 month high of $386.00. The firm has a market capitalization of $23.80 billion, a P/E ratio of 43.30, a price-to-earnings-growth ratio of 2.42 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.08 by $0.29. The firm had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business’s revenue was up 13.8% compared to the same quarter last year. During the same period last year, the firm posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 11.27%.

Analyst Ratings Changes

Several equities research analysts recently commented on WST shares. TD Cowen reaffirmed a “buy” rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. Stephens reissued an “overweight” rating and issued a $360.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $310.00 to $400.00 in a report on Tuesday, June 9th. Citigroup raised their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $368.08.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.